TLP
REGN icon

Tri Locum Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Tri Locum Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-17,516
Closed -$18.4M – 26
2024
Q2 		$18.4M Buy
17,516
+8,949
+104% +$8.68M 4.65% 9
2024
Q1 		$8.25M Sell
8,567
-7,445
-46% -$7.08M 2.86% 15
2023
Q4 		$14.1M Sell
16,012
-3,997
-20% -$3.29M 6.43% 4
2023
Q3 		$16.5M Sell
20,009
-635
-3% -$499K 5.27% 6
2023
Q2 		$14.8M Sell
20,644
-22,745
-52% -$17.5M 5.51% 5
2023
Q1 		$35.7M Buy
+43,389
New +$32.7M 10.86% 1
2022
Q4 		– Sell
-30,115
Closed -$20.7M – 89
2022
Q3 		$20.7M Buy
+30,115
New +$19M 5.69% 5
2022
Q2 		– Sell
-21,477
Closed -$15M – 60
2022
Q1 		$15M Buy
+21,477
New +$13.6M 5.86% 3
2021
Q4 		– Sell
-13,950
Closed -$8.44M – 50
2021
Q3 		$8.44M Sell
13,950
-61,677
-82% -$38.3M 3.35% 13
2021
Q2 		$42.2M Buy
75,627
+10,922
+17% +$5.53M 13.83% 2
2021
Q1 		$30.6M Buy
64,705
+54,282
+521% +$26.4M 7.59% 3
2020
Q4 		$5.04M Buy
+10,423
New +$5.63M 1.83% 17

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Tri Locum Partners's REGN Position: Q3 2024 in Review

Tri Locum Partners sold out of Regeneron Pharmaceuticals (REGN) in Q3 2024, closing a stake of 17,516 shares — an estimated $18.4M sold.

Tri Locum Partners first reported a position in REGN in Q4 2020 and held it in 12 quarters. The position peaked at $42.2M in Q2 2021. 1,388 funds tracked by Wall St. Rank hold REGN as of Q3 2024.

  • Tri Locum Partners reported no remaining Regeneron Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Tri Locum Partners sold 17,516 Regeneron Pharmaceuticals shares in Q3 2024, an estimated $18.4M.
  • Tri Locum Partners first reported a position in Regeneron Pharmaceuticals in Q4 2020 and held it in 12 quarters.
  • Tri Locum Partners's Regeneron Pharmaceuticals position peaked at $42.2M in Q2 2021.
  • 1,388 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2024.

Based on Tri Locum Partners's 13F filing for Q3 2024, filed 14 Nov 2024.